The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review
In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year, immunotherapy modulators inhibiting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2021-05-01
|
| Серія: | Frontiers in Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fonc.2021.663749/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|